(acquired by IBM)
|$2.18 to $73.20||3487%|
|$2.35 to $24.08||925%|
|Cellstar||$1.44 to $13.50||837%|
|Iomega||$3.25 to $13.90||328%|
|Nanophase||$3.75 to $16.75||347%|
|Immunomedics||$1.44 to $29.12||1922%|
|Total Renal Care||$3.12 to $26.95||741%|
|Voxware||$ .90 to $10.31||1046%|
|Corvas||$3.00 to $23.25||675%|
|Cytogen||$2.12 to $17.50||725%|
|Verilink||$3.00 to $14.62||387%|
|GeneLabs||$2.31 to $10.72||364%|
WE CLOSED BIODELIVERY SCIENCES AT $4.12 FOR A 52% GAIN!
Feautured right now in the mid-November Newsletter are a medical device maker that recently received FDA approval for its system to treat people with obesity; while the other is a Channeled Pick which is a biotech that has collaborations with Aclaris, AstraZeneca, and several other pharmas.
BIG NEWS! Both of our recommendations for the next Newsletter are CHANNELED PICKS! Read about our PROVEN CHANNELING STRATEGY!
"I cannot thank you enough for your excellent newsletter... I do believe I have found a new hobby (and a well paying one, at that), thanks to you!"
— B.K. (Contractor in Saudi Arabia)